Combined treatment with anti‐PSMA CAR NK‐92 cell and anti‐PD‐L1 monoclonal antibody enhances the antitumour efficacy against castration‐resistant prostate cancer

BACKGROUND: The chimeric antigen receptor NK‐92 (CAR NK‐92) cell targeting the prostate‐specific membrane antigen (PSMA) has shown antitumour effects in castration‐resistant prostate cancer (CRPC). However, the expression changes of programmed death ligand 1 (PD‐L1) and its mechanisms on CAR NK‐92 a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Fangming, Wu, Liyuan, Yin, Le, Shi, Hui, Gu, Yuchun, Xing, Nianzeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9191826/
https://www.ncbi.nlm.nih.gov/pubmed/35696531
http://dx.doi.org/10.1002/ctm2.901

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9191826/
https://www.ncbi.nlm.nih.gov/pubmed/35696531
http://dx.doi.org/10.1002/ctm2.901

Ejemplares similares